Neue Therapieansätze in der LDL-Cholesterin-Absenkung?

Erhöhte LDL-C-Konzentrationen (LDL-C: Low-Density-Lipoprotein-Cholesterin) sind weiterhin zweifellos ein kausaler Risikofaktor für kardiovaskuläre Ereignisse (ASCVD) [1]. In der Vergangenheit konnte mehrfach in großen randomisierten prospektiven Studien gezeigt werden, dass durch therapeutische LDL-C-Absenkungen parallel weitere kardiovaskuläre Ereignisse vermindert werden [2]. Aus all diesen Studien konnten nun in Abhängigkeit vom kardiovaskulären Risikoprofil LDL-C-Zielwerte definiert werden.

Publikationsverlauf

Artikel online veröffentlicht:
10. September 2021

• Literatur

• 1 Ference BA, Ginsberg HN, Graham I. et al Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459-2472
• 2 Preiss D, Tobert JA, Hovingh GK. et al Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar. J Am Coll Cardiol 2020; 75: 1945-1955
• 3 Hooper AJ, Burnett JR. Recent developments in the genetics of LDL deficiency. Curr Opin Lipidol 2013; 24: 111-115
• 4 Julius U, Kuss S, Tselmin S. et al Why Some Patients Undergoing Lipoprotein Apheresis Therapy Develop New Cardiovascular Events?. J Cardiovasc Dev Dis 2020; 07: 25
• 5 Mohamed F, Botha TC, Raal FJ. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr Opin Lipidol 2021; 32: 213-218
• 6 Carmena R, Ascaso JF, Redon J. Chronic kidney disease as a cardiovascular risk factor. J Hypertens 2020; 38: 2110-2121
• 7 Mach F, Baigent C, Catapano AL. et al 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188
• 8 Ray KK, Molemans B, Schoonen WM. et al EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2020 Aug 28 zwaa047
• 9 Johannesen CDL, Mortensen MB, Langsted A. et al Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol 2021; 77: 1439-1450
• 10 Ballantyne CM, Bays H, Catapano AL. et al Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther 2021; 35: 853-864
• 11 Nordestgaard BG, Nicholls SJ, Langsted A. et al Advances in lipid-lowering therapy through gene-silencing technologies. Nat Rev Cardiol 2018; 15: 261-272
• 12 Sabatine MS, Giugliano RP, Keech AC. et al Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-1722
• 13 Schwartz GG, Steg PG, Szarek M. et al Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379: 2097-2107
• 14 Laina A, Gatsiou A, Georgiopoulos G. et al RNA Therapeutics in Cardiovascular Precision Medicine. Front Physiol 2018; 09: 953
• 15 Wright RS, Ray KK, Raal FJ. et al Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. J Am Coll Cardiol 2021; 77: 1182-1193
• 16 Markham A. Evinacumab: First Approval. Drugs 2021; 81: 1101-1105
• 17 Gaudet D, Gipe DA, Pordy R. et al ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. N Engl J Med 2017; 377: 296-297
• 18 Raal FJ, Rosenson RS, Reeskamp LF. et al Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med 2020; 383: 711-720